…
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Greenwich Lifesciences, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ developing therapeutic candidates. Long-term growth drivers include advancement of research and development programs, successful commercialization of any approved products, and strategic partnerships that could expand the pipeline. Investors may find exposure to potential upside from program progress and partnership outcomes attractive while accepting typical early-stage biotech volatility.
The most important investment risks are clinical and regulatory setbacks, the need for additional financing and resulting dilution, a limited operating history and challenges in achieving commercial execution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -19.36M | -15.79M | -8.89M | -7.83M | -4.57M |
| Net income | -19.36M | -15.79M | -8.89M | -7.61M | -4.54M |
| Selling general administrative | 2.23M | 3.06M | 1.63M | 1.56M | 1.04M |
| Selling and marketing expenses | - | - | 0.00M | - | - |
| Gross profit | -0.00M | -0.00M | -0.00M | - | - |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Ebit | -19.36M | -15.79M | -9.33M | -8.04M | -4.60M |
| Ebitda | -19.36M | -15.79M | -9.32M | -8.04M | -4.59M |
| Depreciation and amortization | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Non operating income net other | - | - | - | - | 0.03M |
| Operating income | -19.45M | -16.01M | -9.33M | -8.04M | -4.60M |
| Other operating expenses | 19.45M | 16.01M | 9.33M | 8.04M | 4.60M |
| Interest expense | - | - | - | 0.22M | 0.03M |
| Interest income | 0.09M | 0.22M | 0.45M | 0.22M | 0.03M |
| Net interest income | 0.09M | 0.22M | 0.45M | 0.22M | 0.03M |
| Income tax expense | - | - | -0.00M | -0.22M | -0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 19.45M | 16.01M | 9.33M | 8.04M | 4.60M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | - | - |
| Total other income expense net | 0.09M | 0.22M | 0.44M | 0.22M | 0.03M |
| Net income from continuing ops | -19.36M | -15.79M | -8.94M | -7.83M | -4.57M |
| Net income applicable to common shares | - | - | - | - | -4.57M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 6.18M | 4.09M | 6.99M | 13.48M | 27.22M |
| Intangible assets | - | 0.00M | 0.01M | 0.01M | 0.01M |
| Total liab | 5.82M | 1.56M | 0.29M | 0.26M | 0.39M |
| Total stockholder equity | 0.35M | 2.53M | 6.70M | 13.21M | 26.83M |
| Other current liab | 0.95M | 0.38M | 0.26M | 0.26M | 0.16M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -87.14M | -66.15M | -50.36M | -41.47M | -33.65M |
| Other assets | - | 0.00M | 0.00M | -0.01M | -0.01M |
| Cash | 6.18M | 4.09M | 6.99M | 13.47M | 27.20M |
| Total current liabilities | 5.82M | 1.56M | 0.29M | 0.26M | 0.39M |
| Net debt | -6.18M | -4.09M | -6.99M | -13.47M | -27.20M |
| Other stockholder equity | 87.48M | 68.67M | 57.05M | 54.67M | 60.47M |
| Total current assets | 6.18M | 4.09M | 6.99M | 13.47M | 27.20M |
| Net tangible assets | - | - | - | - | 26.82M |
| Accounts payable | 4.87M | 1.18M | 0.04M | 0.00M | 0.22M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Common stock total equity | - | - | - | - | 0.01M |
| Retained earnings total equity | - | - | - | - | -33.65M |
| Non currrent assets other | - | - | 0.00M | - | - |
| Non current assets total | 0.00M | 0.00M | 0.01M | 0.01M | 0.01M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | - | -0.39M |
| Net borrowings | - | - | - | - | -0.28M |
| Total cash from financing activities | 12.00M | 4.37M | 0.00M | -7.54M | 2.84M |
| Change to operating activities | - | - | - | - | 0.14M |
| Net income | -19.36M | -15.79M | -8.89M | -7.83M | -4.57M |
| Change in cash | 2.09M | -2.90M | -6.48M | -13.74M | -1.46M |
| Begin period cash flow | 4.09M | 6.99M | 13.47M | 27.20M | 28.66M |
| End period cash flow | 6.18M | 4.09M | 6.99M | 13.47M | 27.20M |
| Total cash from operating activities | -9.91M | -7.27M | -6.48M | -6.20M | -4.29M |
| Issuance of capital stock | 11.85M | 4.37M | 0.00M | - | 3.11M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Sale purchase of stock | - | - | 0.00M | -7.54M | 3.11M |
| Other cashflows from financing activities | 12.00M | 4.37M | - | - | -0.28M |
| Change to netincome | - | - | - | - | 0.66M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Cash and cash equivalents changes | - | - | - | - | -1.46M |
| Change in working capital | 2.64M | 1.27M | 0.03M | -0.12M | -0.39M |
| Stock based compensation | 6.80M | 7.25M | 2.38M | 1.74M | 0.66M |
| Other non cash items | 2.64M | 1.27M | 0.04M | - | -0.38M |
| Free cash flow | -9.91M | -7.27M | -6.48M | -6.20M | -4.29M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| GLSI Greenwich Lifesciences Inc |
4.24 30.81% |
18.00 | - | - | - | 75.58 | -21.23 |
| NVO Novo Nordisk A/S |
-0.80 1.91% |
40.80 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.08 0.39% |
535.71 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.09 0.95% |
961.49 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Snehal S. Patel | CEO, CFO & Director | 1963 |
| Mr. Eric Rothe | Founder & Independent Director | 1975 |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | 1950 |
| Dr. Jaye L. Thompson Ph.D. | VP of Clinical & Regulatory Affairs | 1966 |
| Dr. Christine T. Fischette Ph.D. | VP of Bus. Devel. | 1951 |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | 1966 |
| Dr. Christine T. Fischette Ph.D. | VP of Business Development | 1951 |
| Mr. Snehal S. Patel | CEO, CFO & Director | 1964 |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | 1951 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.